









Markets
/
Stocks
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX

31.980USD

+0.160+0.50%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

9.10BMarket Cap

10.32P/E TTM



TG Therapeutics Inc

31.980

+0.160+0.50%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of TG Therapeutics Inc

Currency: USD Updated: 2026-03-26

Key Insights

TG Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.17.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TG Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

51 / 157

Overall Ranking

139 / 4546

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

TG Therapeutics Inc Highlights

StrengthsRisks

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 163.75% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 616.29M.

Fairly Valued

The company’s latest PE is 10.32, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 103.04M shares, decreasing 14.69% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 35.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.19.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

44.167

Target Price

+46.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of TG Therapeutics Inc is 8.36, ranking 61 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 192.57M, representing a year-over-year increase of 78.00%, while its net profit experienced a year-over-year increase of 1.26%.

Score

Industry at a Glance

Previous score

8.36

Change



Financials

5.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.19

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

TG Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of TG Therapeutics Inc is 4.54, ranking 155 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 10.32, which is 2488.64% below the recent high of 267.17 and 3442.77% above the recent low of -345.00.

Score

Industry at a Glance

Previous score

4.54

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of TG Therapeutics Inc is 7.56, ranking 102 out of 157 in the Pharmaceuticals industry. The average price target is 49.00, with a high of 60.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

7.56

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

44.167

Target Price

+46.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

TG Therapeutics Inc

TGTX

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of TG Therapeutics Inc is 9.25, ranking 7 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 34.05 and the support level at 28.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.09

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.639

Buy

RSI(14)

61.387

Neutral

STOCH(KDJ)(9,3,3)

81.904

Buy

ATR(14)

1.515

High Vlolatility

CCI(14)

122.283

Buy

Williams %R

8.581

Overbought

TRIX(12,20)

0.143

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

30.908

Buy

MA10

30.318

Buy

MA20

29.625

Buy

MA50

29.758

Buy

MA100

30.432

Buy

MA200

32.172

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of TG Therapeutics Inc is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 64.90%, representing a quarter-over-quarter increase of 1.55%. The largest institutional shareholder is The Vanguard, holding a total of 15.80M shares, representing 9.90% of shares outstanding, with 0.90% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

18.83M

-1.57%

The Vanguard Group, Inc.

Star Investors

15.49M

-1.83%

Weiss (Michael S)

9.16M

-33.77%

State Street Investment Management (US)

8.10M

+6.33%

ClearBridge Investments, LLC

4.64M

+52.15%

Geode Capital Management, L.L.C.

3.44M

-1.33%

Soleus Capital Management, L.P.

3.84M

+71.34%

Congress Asset Management Company, LLP

1.00M

Two Sigma Investments, LP

1.32M

+78.79%

Hood River Capital Management LLC

1.55M

-0.94%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TG Therapeutics Inc is 7.15, ranking 43 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. TG Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.